Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LIPE | Q05469 | 1/20 | 0.51 |
| ▸ | GCK | P35557 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | PPIA | P62937 | 1/20 | 0.49 |
| ▸ | ATP4A | P20648 | 1/20 | 0.49 |
| ▸ | ATP4B | P51164 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12330519 | 0.84 | NPC1 (0.48) | LTA4HMAPK14L3MBTL1MAPTMAPK1 | |
| SCHEMBL12301192 | 0.83 | NPC1 (0.70) | LTA4HMAPK14HTTSMN1; SMN2ABCB1 | |
| SCHEMBL1562664 | 0.82 | CYP11B1 (0.59) | LTA4HMAPK14ABCB1HTR1ADRD2 | |
| SCHEMBL14001713 | 0.82 | NPC1 (0.46) | LTA4HMAPK14L3MBTL1MAPTMAPK1 | |
| SCHEMBL6244117 | 0.82 | MAPT (0.45) | LTA4HMAPK14L3MBTL1MAPTMAPK1 | |
| SCHEMBL16356781 | 0.80 | L3MBTL1 (0.65) | LTA4HMAPK14L3MBTL1MAPTMAPK1 | |
| SCHEMBL8526782 | 0.79 | LTA4H (0.66) | LTA4HMAPK14L3MBTL1MAPTMAPK1 | |
| SCHEMBL18523485 | 0.79 | LTA4H (0.60) | LTA4HMAPK14L3MBTL1MAPTMAPK1 | |
| SCHEMBL7023075 | 0.79 | LTA4H (0.60) | LTA4HMAPK14L3MBTL1MAPTMAPK1 | |
| SCHEMBL14514408 | 0.79 | LTA4H (0.60) | LTA4HMAPK14L3MBTL1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349989-B | Pyrano bipyridine compound | 卫材R&D管理有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-20200383959-A1 | THERAPEUTIC AGENT CONTAINING PYRANODIPYRIDINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-10 | — | — | US | disclosed |
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| EP-3622954-A1 | THERAPEUTIC AGENT CONTAINING PYRANODIPYRIDINE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2020-03-18 | — | — | EP | disclosed |
| CN-110520126-A | Therapeutic agents containing pyrano-bipyridine compounds | EISAI R&D MAN CO LTD | 2019-11-29 | — | — | CN | disclosed |
| CN-110218207-A | Cumarin heterozygosis pyridine compounds and its preparation and application with iron chelating and monoamine oxidase B inhibitory activity | 浙江工业大学 | 2019-09-10 | — | — | CN | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| EP-3378863-A1 | PYRANODIPYRIDINE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-1748044-A1 | THIAZOLE COMPOUND AND USE THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-31 | — | — | EP | disclosed |
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-1219607-A1 | INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| CN-1158121-A | Indolizine sPLA2Inhibitors | LILLY CO ELI (US) | 1997-08-27 | — | — | CN | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383959-A1 | THERAPEUTIC AGENT CONTAINING PYRANODIPYRIDINE COMPOUND | PSEN1, MAPT, PSEN2 | LTA4H 3714/4885MAPK14 161/4885L3MBTL1 4561/4885 |
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | LTA4H 3466/4885MAPK14 1810/4885L3MBTL1 1604/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | LTA4H 904/4885MAPK14 2623/4885L3MBTL1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.